Myungmoon Pharm co.,Ltd (017180.KS) Stock

017180.KS logo

Myungmoon Pharm co.,Ltd

017180.KSSouth Korea
Healthcare

Company profile

Myungmoon Pharm reported revenue of 195.25 billion KRW for fiscal year 2025, up 4.7% from fiscal year 2024. Its largest business segment, Pharmaceutical Sector, brought in 96% of segment revenue in fiscal year 2024; South Korea was the largest region with 98%. Our analysis of its filings shows revenue growing from 169.57 billion KRW in fiscal year 2023 to 195.25 billion KRW in fiscal year 2025, 7.3% a year on average. Myungmoon Pharm reports about 319 full-time employees.

What stands out

  • It returned to a profit in fiscal year 2025, 1.90 billion KRW, after 2 years of net losses (3.03 billion KRW in fiscal year 2024).
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Myungmoon Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Seok-Min Woo19.1 %19.10%
  • Myungmoon Pharm Co.,Ltd1.55%
  • Jung-bin Woo1.097 %1.10%
  • Cheol-Han Bae0.9959 %1.00%
  • Ju-Han Kim0.7629 %0.76%

Share of the company, as of September 25, 2026

Leadership

  • Cheol-han Bae — Chief Executive Officer
  • Kyu-Huok Lee — Chairperson & President, 76
  • Yong-Kyeong Seong — Managing Director and Development Support Director, 61
  • Won-Sann Seo — Director of Chungcheong & Honam Region and Director, 66

How much revenue does Myungmoon Pharm make?

Myungmoon Pharm reported 195.25 billion KRW in revenue for fiscal year 2025, up 4.7% from 186.44 billion KRW in fiscal year 2024.

What is Myungmoon Pharm's largest business segment?

Pharmaceutical Sector, with 200.14 billion KRW or 96% of segment revenue in fiscal year 2024. Next: Services Segment (4%).

Where does Myungmoon Pharm make most of its revenue?

South Korea: 98% of revenue by region in fiscal year 2024, followed by Overseas (2%).

What companies are similar to Myungmoon Pharm?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ildong Holdings Co., Ltd. (000230.KS), Icure Pharmaceutical Incorporation (175250.KQ), Jin Yang Pharmaceutical Co., Ltd. (007370.KQ), Bcworld Pharm. Co., Ltd. (200780.KQ).

Has Myungmoon Pharm made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 6.86 billion KRW; FY2022, 7.87 billion KRW; FY2023, a loss of 4.52 billion KRW; FY2024, a loss of 3.03 billion KRW; FY2025, 1.90 billion KRW. It reported a net loss in 3 of these 5 years.

How has Myungmoon Pharm's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 137.76 billion KRW; FY2022, 152.13 billion KRW; FY2023, 169.57 billion KRW; FY2024, 186.44 billion KRW; FY2025, 195.25 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees319
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
7, Gangnam-daero, Seoul, 06258
Phone
82 2 6711 2000
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Myungmoon Pharm co.,Ltd (017180.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/017180.KS

LinkedInLinkedInXXYouTubeYouTube